<PAGE>
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
(Mark One)
X QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
----- EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 1998
or
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
---- EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO ______
Commission File Number: 0-22352
----------------------
HOLOPHANE CORPORATION
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
----------------------
DELAWARE 31-1288751
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
250 EAST BROAD STREET
SUITE 1400
COLUMBUS, OHIO
43215
(Address of principal executive offices)
(614) 224-3134
Registrant's telephone number, including area code
----------------------
Indicate by check mark whether the registrant (1) has filed all reports to
be filed by Section 13 or Section 15(d) of the Securities Exchange Act of 1934
during the preceding 12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been subject to such filing
requirements for the past 90 days. Yes [x] No [ ]
The number of shares outstanding of registrant's Common Stock as of March
31, 1998: 10,971,496
<PAGE>
HOLOPHANE CORPORATION
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 1998
INDEX
<TABLE>
<S> <C>
PART I. FINANCIAL INFORMATION
Condensed Consolidated Statements of Income for
the three months ended March 31, 1998 and
March 31, 1997 (unaudited) . . . . . . . . . . . . . . . . . 1
Condensed Consolidated Balance Sheets as of
March 31, 1998 (unaudited) and December 31, 1997 . . . . . . 2
Condensed Consolidated Statements of Cash
Flows for the three months ended March 31, 1998
and March 31, 1997 (unaudited) . . . . . . . . . . . . . . . 3
Condensed Consolidated Statement of Stockholders'
Equity as of March 31, 1998 (unaudited). . . . . . . . . . . 4
Notes to Condensed Consolidated
Financial Statements . . . . . . . . . . . . . . . . . . . . 5
Management Discussion and Analysis . . . . . . . . . . . . . 6
PART II. OTHER INFORMATION. . . . . . . . . . . . . . . . . . . . . . 7
Signature. . . . . . . . . . . . . . . . . . . . . . . . . . 8
</TABLE>
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED)
(in thousands except per share data)
<TABLE>
<CAPTION>
Three Month Period Ended
----------------------------
March 31, March 31,
1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Net Sales $47,247 $46,408
Cost of Goods Sold 28,915 28,526
------- -------
Gross Margin 18,332 17,882
Selling and Administrative Expenses 10,929 10,871
Research and Development 1,530 1,467
Other Expenses 490 168
------- -------
Operating Income 5,383 5,376
Interest Expense 387 478
Interest Income (149) (97)
------- -------
Income Before Income Taxes 5,145 4,995
Provision for Income Taxes 1,881 1,885
------- -------
Net Income 3,264 3,110
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
Basic Earnings Per Share $0.30 $0.27
- --------------------------------------------------------------------------------
Diluted Earnings Per Share $0.29 $0.26
- --------------------------------------------------------------------------------
Weighted Average Number of Shares Outstanding:
Basic 11,029 11,445
Diluted 11,381 11,796
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
1
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
($ in thousands)
<TABLE>
<CAPTION>
March 31, December 31,
1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
ASSETS
- --------------------------------------------------------------------------------
Cash and Equivalents $ 9,459 $ 11,709
Receivables 26,244 29,903
Inventory 15,106 12,651
Other Current Assets 3,705 3,988
- --------------------------------------------------------------------------------
TOTAL CURRENT ASSETS 54,514 58,251
- --------------------------------------------------------------------------------
Plant, Property and Equipment, Net 43,089 42,102
Intangibles 21,019 21,285
Other Assets 6,014 5,158
- --------------------------------------------------------------------------------
TOTAL ASSETS $124,636 $126,796
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
LIABILITIES AND STOCKHOLDERS' EQUITY
- --------------------------------------------------------------------------------
Current Liabilities $ 23,228 $ 24,912
Current Portion of Long Term Debt 359 6,610
Long Term Debt 16,207 12,964
Other Long Term Liabilities 7,739 7,207
Stockholders' Equity 77,103 75,103
- --------------------------------------------------------------------------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $124,636 $126,796
- --------------------------------------------------------------------------------
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these financial statements.
2
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS (UNAUDITED)
($ in thousands)
<TABLE>
<CAPTION>
Three Month Period Ended
------------------------
March 31 March 31
1998 1997
- --------------------------------------------------------------------------------
<S> <C> <C>
Net cash flow provided by operating activities: $ 6,958 $ 9,215
- --------------------------------------------------------------------------------
Investing activities:
Capital expenditures (3,481) (1,553)
Other (659) (751)
------- -------
Net cash used in investing activities: (4,140) (2,304)
- --------------------------------------------------------------------------------
Financing activities:
Principal payments of long term debt (21,760) (3,149)
Proceeds from revolving debt 18,752 0
Purchase of treasury shares (2,391) (2,971)
Proceeds from the sale of treasury shares 275 2
------- -------
Net cash used in financing activities: (5,124) (6,118)
- --------------------------------------------------------------------------------
Effects of exchange rate changes on cash: 56 23
- --------------------------------------------------------------------------------
Net increase/(decrease) in cash and equivalents: (2,250) 816
- --------------------------------------------------------------------------------
Cash and equivalents at beginning of period: 11,709 8,072
- --------------------------------------------------------------------------------
Cash and equivalents at end of period: $ 9,459 $ 8,888
- --------------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these financial statements.
3
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY
(Unaudited $ in thousands)
<TABLE>
<CAPTION>
ACCUMULATED
OTHER COMMON STOCK ADDITIONAL
COMPREHENSIVE RETAINED COMPREHENSIVE ------------ PAID-IN
INCOME EARNINGS INCOME/(Loss) SHARES AMOUNT CAPITAL
- -----------------------------------------------------------------------------------------------------------------------------
<S> <C> <C> <C> <C> <C> <C>
BALANCE AT DECEMBER 31, 1997 $ 49,150 $ (1,427) 11,895,861 $ 119 $ 43,143
- -----------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------
Comprehensive income
Net income $ 3,264 3,264
Other comprehensive
income, net of tax
Foreign currency
translation
adjustments 148
-----------
Other comprehensive
income 148 148
-----------
Comprehensive income $ 3,412
-----------
-----------
Shares used for
acquisitions 91
Purchase of treasury
shares
Stock options exercised,
including related tax
benefits (352)
- -----------------------------------------------------------------------------------------------------------------------------
BALANCE AT MARCH 31, 1998 $ 52,414 $ (1,279) 11,895,861 $ 119 $ 42,882
- -----------------------------------------------------------------------------------------------------------------------------
- -----------------------------------------------------------------------------------------------------------------------------
</TABLE>
<TABLE>
<CAPTION>
TREASURY STOCK
-------------- STOCKHOLDERS'
SHARES AMOUNT EQUITY
- -----------------------------------------------------------------------------
<S> <C> <C> <C>
BALANCE AT DECEMBER 31, 1997 880,014 $ (15,882) $ 75,103
- -----------------------------------------------------------------------------
- -----------------------------------------------------------------------------
Comprehensive income
Net income 3,264
Other comprehensive
income, net of tax
Foreign currency
translation
adjustments
Other comprehensive
income 148
Comprehensive income
Shares used in
acquisition (28,675) 613 704
Purchase of treasury
shares 99,200 (2,391) (2,391)
Stock options exercised,
including related tax
benefits (26,174) 627 275
- -----------------------------------------------------------------------------
BALANCE AT MARCH 31, 1998 924,365 $ (17,033) $ 77,103
- -----------------------------------------------------------------------------
- -----------------------------------------------------------------------------
</TABLE>
The accompanying notes are an integral part of these consolidated financial
statements.
4
<PAGE>
HOLOPHANE CORPORATION AND SUBSIDIARIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
BASIS OF PRESENTATION - The condensed consolidated balance sheet as of March 31,
1998, and the condensed consolidated statements of income, cash flows and
stockholders' equity for the three months ended March 31, 1998 and March 31,
1997 have been prepared by the Company, without audit. In the opinion of
management, all adjustments, which include only normal recurring adjustments,
necessary to present fairly the financial position, results of operations,
changes in stockholders' equity and changes in cash flows for all periods
presented have been made.
Certain information and footnote disclosures normally included in financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted. These consolidated financial statements should
be read in conjunction with the financial statements and notes thereto included
in the Company's December 31, 1997 annual report on Form 10-K. The results of
operations for the three month period ended March 31, 1998 are not necessarily
indicative of the operating results for the full year.
CLASSIFICATION OF INVENTORY
(in thousands)
<TABLE>
<CAPTION>
(Unaudited)
March 31, December 31,
1998 1997
----------- ------------
<S> <C> <C>
Raw Materials $ 8,857 $ 7,610
Work in Process 4,716 3,850
Finished Goods 2,237 1,838
------- -------
TOTAL 15,810 13,298
Less Valuation Allowance (704) (647)
------- -------
TOTAL $15,106 $12,651
------- -------
------- -------
</TABLE>
5
<PAGE>
MANAGEMENT DISCUSSION AND ANALYSIS
COMPARISON OF FIRST QUARTER 1998 TO FIRST QUARTER 1997
Worldwide net sales for the first quarter of 1998 were $47.2 million, up 2% from
first quarter 1997. First quarter sales in the United States increased 1%
compared to 1997. European sales in local currency were up approximately 3%
compared to first quarter 1997. Canadian sales were up 5% in local currency
compared to 1997.
Operating income was $5.4 million, level with 1997. Higher volume with improved
margin was offset by higher selling, administrative and other expenses. Total
operating expenses in the quarter were $12.9 million, up from $12.5 million in
1997.
Net interest expense decreased by $0.1 million in 1998 due to lower outstanding
balances. Debt decreased $3.0 million.
Net income and diluted earnings per share were $3.3 million and $0.29,
respectively, compared with $3.1 million and $0.26 in 1997. Basic earnings per
share were $0.30 compared to $0.27.
CAPITAL RESOURCES, LIQUIDITY AND OTHER
In March, the company completed the refinancing of its multibank term and
revolving credit agreement that was put in place at the time of the 1993 Initial
Public Offering. The new credit facility, an unsecured $30 million three-year
revolving credit commitment through National City Bank, will simplify structure,
reduce interest costs and more appropriately reflects the financial strength of
the company. In March, the company expensed unamortized debt issuance costs
relating to the old credit agreement which reduced diluted earnings per share by
$0.01 in the quarter.
Working capital was $30.9 million as of March 31, 1998, up approximately $4.2
million from year-end 1997 due primarily to the reclassification of the current
portion of debt out of current liabilities into long-term debt.
Cash on hand, funds generated from operations and amounts available under the
credit agreement are expected to adequately fulfill Holophane's anticipated
requirements for the remainder of 1998 and in the foreseeable future.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995: Except for historical information contained herein, the matters set forth
in this filing constitute forward-looking statements that are dependent on
certain risks and uncertainties including such factors, among others, as weather
conditions throughout the remainder of the fiscal year, the general state of the
national economy and other risks detailed in the Company's Securities Exchange
Act of 1934 filings.
6
<PAGE>
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
Not Applicable.
ITEM 2. CHANGES IN SECURITIES
Not Applicable.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not Applicable.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
Not Applicable.
ITEM 5. OTHER INFORMATION
Not Applicable.
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
Not Applicable.
7
<PAGE>
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, Holophane
has duly caused this report to be signed on its behalf of the undersigned
thereunto duly authorized.
HOLOPHANE CORPORATION
---------------------
(Registrant)
DATE: APRIL 17, 1998 /s/ Bruce A. Philp
------------------------------ -----------------------------
Bruce A. Philp
Vice President, Finance and
Chief Financial Officer
8
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-1998
<PERIOD-END> MAR-31-1998
<CASH> 9,459
<SECURITIES> 0
<RECEIVABLES> 27,395
<ALLOWANCES> 1,151
<INVENTORY> 15,106
<CURRENT-ASSETS> 54,514
<PP&E> 93,882
<DEPRECIATION> 50,793
<TOTAL-ASSETS> 124,636
<CURRENT-LIABILITIES> 23,587
<BONDS> 16,207
0
0
<COMMON> 119
<OTHER-SE> 76,984
<TOTAL-LIABILITY-AND-EQUITY> 124,636
<SALES> 47,247
<TOTAL-REVENUES> 47,247
<CGS> 28,915
<TOTAL-COSTS> 12,459
<OTHER-EXPENSES> 490
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 387
<INCOME-PRETAX> 5,145
<INCOME-TAX> 1,881
<INCOME-CONTINUING> 3,264
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> 3,264
<EPS-PRIMARY> 0.30
<EPS-DILUTED> 0.29
</TABLE>
